Keyphrases
Comorbidity
100%
COVID-19
91%
Asthma
66%
Population-based
63%
Primary Care
58%
Scotland
54%
Confidence Interval
42%
Type 2 Diabetes Mellitus (T2DM)
34%
Spain
33%
Meta-analysis
33%
Cardiovascular Disease
33%
Germany
30%
Hospitalization
30%
Chronic Obstructive Pulmonary Disease
30%
Older People
29%
Nested Case-control Study
28%
Electronic Health Records
28%
External Validation
27%
Interrupted Time Series Regression
25%
South Korea
25%
Hazard Ratio
25%
Population Cohort Study
25%
Multinational Network
25%
Sectional Analysis
25%
Acute Kidney Injury
24%
Fluoroquinolones
24%
Competing Risks
23%
COVID-19 Pandemic
22%
Incidence Rate
22%
Time Series Regression Analysis
21%
France
21%
European Medicines Agency
21%
Beta-blockers
21%
International Networks
21%
Risk Prediction Tool
20%
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
20%
Europe
20%
COVID-19 Patients
20%
Clinical Practice Research Datalink
20%
Randomized Controlled Trial
19%
Retrospective Cohort Study
19%
Influenza
19%
Label Change
18%
Cardiovascular Risk Prediction
18%
Chronic Obstructive Pulmonary Disease Patient
18%
Performance Prediction
18%
Methodological Considerations
18%
Respiratory Effects
18%
People with Dementia
18%
Interrupted Time Series
18%
Medicine and Dentistry
COVID-19
84%
Cohort Analysis
80%
Primary Health Care
58%
Comorbidity
55%
Cardiovascular Disease
39%
Medicine
35%
Diseases
34%
Cohort Effect
32%
Electronic Health Record
31%
Cross Sectional Study
30%
Multiple Chronic Conditions
29%
Randomized Controlled Trial
28%
Maturity Onset Diabetes of the Young
26%
Time Series Analysis
26%
Cardiovascular System
26%
Systematic Review
25%
Cardiovascular Risk
20%
Acute Kidney Injury
20%
Observational Study
19%
Prevalence
19%
Clinical Population
18%
Odds Ratio
17%
Hazard Ratio
16%
Apoplexy
16%
Chronic Obstructive Pulmonary Disease
15%
Pharmacovigilance
14%
Thrombosis
14%
Read Code
13%
Thrombocytopenia
13%
Symptomatic Treatment
12%
Human Immunodeficiency Virus
12%
Hip Fracture
12%
Fragility Fracture
12%
Pancreas Cancer
12%
Systematized Nomenclature of Medicine
12%
General Medicine
12%
Antidepressant
12%
Sulfonylurea
12%
Glycon
11%
Clinical Guideline
11%
Meta-Analysis
11%
Clinical Trial
10%
Malignant Neoplasm
10%
Adverse Event
10%
Health Outcomes
10%
Frailty Index
10%
Mental Health
10%
Glucagon-Like Peptide-1 Agonist
9%
Sodium Glucose Cotransporter 2 Inhibitor
9%
Decision Making
9%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
92%
Diseases
65%
Asthma
53%
Cardiovascular Disease
35%
Prevalence
35%
Comorbidity
34%
Coronavirinae
34%
Quinolone Derivative
33%
Randomized Controlled Trial
33%
Case-Control Study
27%
Observational Study
26%
Pharmacovigilance
25%
Chronic Obstructive Lung Disease
23%
Acute Kidney Failure
23%
Non Insulin Dependent Diabetes Mellitus
23%
Adverse Event
22%
Multiple Chronic Conditions
22%
Thrombocytopenia
19%
Fragility Fracture
18%
Beta Adrenergic Receptor Blocking Agent
18%
Antipsychotic
18%
Antidepressant
18%
Thrombosis
17%
Infection
17%
COVID-19 Vaccine
14%
Antibiotics
14%
Cross-Sectional Study
14%
Non-Steroidal Anti-Inflammatory Drug
13%
Syndrome
13%
Hydroxychloroquine
13%
Dipeptidyl Carboxypeptidase Inhibitor
12%
Drug Utilization
12%
Risk Communication
12%
Tendon Rupture
12%
Hip Fracture
12%
Diclofenac
12%
Drug Development
12%
Adrenergic Receptor
12%
Pandemic
12%
Bisphosphonic Acid Derivative
11%
Cerebrovascular Accident
11%
Monotherapy
11%
SARS Coronavirus
11%
Sulfonylurea
11%
Azithromycin
10%
Analgesic Agent
10%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
10%
Diuretics
9%
sodium glucose cotransporter-2 inhibitors
9%
Congestive Heart Failure
9%